915034-80-9

Upstream product

• 60494-73-7 (2-methoxycarbonylbenzyl)triphenylphosphonium bromide 
• 89-71-4 2-Methyl-benzoic acid methyl ester 
• 2417-73-4 methyl 2-bromomethylbenzoate 
• 915034-78-5 2-[(E/Z)-2-(3-nitrophenyl)-vinyl]-benzoic acid methyl ester 

Downstream Products

• 1354005-15-4 (R)-3-[(S)-bromo(3-nitrophenyl)methyl]isobenzofuran-1(3H)-one 
• 66672-06-8 2-[2-(3-acetylaminophenyl)-ethyl]-benzoic acid 
• 1027535-57-4 2-(4-nitrophenylamino)-10,11-dihydro-dibenzo[a,d]cyclohepten-5-one 
• 924266-48-8 2-(2-nitrophenylamino)-10,11-dihydro-dibenzo[a,d]cyclohepten-5-one 
• 15196-54-0 2-[2-(3-aminophenyl)-ethyl]-benzoic acid 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: Novel p38 MAP kinase inhibitors

The pathogenesis of chronic inflammatory diseases is promoted by various pro-inflammatory cytokines. p38 MAP kinase seems to be a valid target as it controls proinflammatory cytokine levels on both transcriptional and translational levels. Starting from benzophenone-type inhibitors, a rigidisation strategy lead to 3-amino-6,11-dihydro-dibenzo[b,e]thiepin-11-one, phenylamino-substituted 6,11-dihydro-dibenzo-[b,e]oxepin-11-ones, and dibenzo[a,d]cyclohepten-5-ones. Synthesis, p38 inhibition, and CYP-inhibition of selected compounds are described.

DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS

The present invention relates to compounds of formula (I), in which R1, R2, R3, R4, X and Y have the meanings indicated in the description. These compounds have immuno-modulating effects, as well as an inhibiting or regulating effect on the release of IL-1β and/or TNF-α. They can therefore be used for the treatment of diseases associated with a disturbance of the immune system.